Investigational drug · Phase 2
SL-325
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Crohn's Disease, Hidradenitis Suppurativa (HS).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "SL-325"
First trial start
2026
Nov 9, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SL-325", any sponsor or status.
Conditions studied
As listed on its trial records.
- Crohn's Disease
- Hidradenitis Suppurativa (HS)
Approved drugs for the same conditions: Crohn's disease · Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "SL-325" as an intervention, largest first.
- A Study of SL-325 in Crohn's Disease PatientsPivotal-lookingRecruiting
Shattuck Labs, Inc.Industry
NCT07753850 · 232 participants (planned) · Start Nov 9, 2026 · Primary completion Jul 2028
Drug: SL-325; Placebo · For: Crohn's Disease
Sites: Little Rock, Arkansas; Oxnard, California; Temple City, California · 20 sites in all
- A Study of SL-325 in Participants With Hidradenitis SuppurativaPivotal-lookingNot yet recruiting
Shattuck Labs, Inc.Industry
NCT07934017 · 150 participants (planned) · Start Jan 2027 · Primary completion Feb 2028
Drug: SL-325; Placebo · For: Hidradenitis Suppurativa (HS)
Shattuck Labs, Inc.Industry
NCT07158437 · 72 participants · Start Sep 18, 2025 · Primary completion Jul 16, 2026
Drug: SL-325 · For: Healthy Volunteers
Sites: Lincoln, Nebraska
Newest research
PubMed records naming it or its code names, newest first.
- Targeting the TL1A pathway in inflammatory bowel disease: mechanistic insights and emerging therapeutic pipeline.
Quraishi MN, Jairath V, Al-Bawardy B · Inflamm Bowel Dis 2026
- Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3/TL1A axis in inflammatory bowel disease.
Hussain M, Lai AY, Franklin D, et al. · Inflamm Bowel Dis 2026
Also in development for Crohn's Disease
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- DuvakitugSAR447189, TEV-48574 APhase 36 trials
Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis
- JNJ-78934804JNJ-4804Phase 34 trials
Johnson & Johnson (Janssen) · Colitis, Ulcerative, Crohn's Disease, Crohn Disease
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
- ABBV-701Phase 22 trials
AbbVie · Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.